Phosphorothioate Oligonucleotides
"Phosphorothioate Oligonucleotides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Modified oligonucleotides in which one of the oxygens of the phosphate group is replaced with a sulfur atom.
| Descriptor ID |
D054735
|
| MeSH Number(s) |
D13.695.578.424.575
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phosphorothioate Oligonucleotides".
Below are MeSH descriptors whose meaning is more specific than "Phosphorothioate Oligonucleotides".
This graph shows the total number of publications written about "Phosphorothioate Oligonucleotides" by people in this website by year, and whether "Phosphorothioate Oligonucleotides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphorothioate Oligonucleotides" by people in Profiles.
-
Mukherjee P, Aksamitiene E, Alex A, Shi J, Bera K, Zhang C, Spillman DR, Marjanovic M, Fazio M, Seth PP, Frazier K, Hood SR, Boppart SA. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging. Nucleic Acid Ther. 2022 06; 32(3):163-176.
-
Zaslavsky A, Adams M, Cao X, Yamaguchi A, Henderson J, Busch-?stergren P, Udager A, Pitchiaya S, Tourdot B, Kasputis T, Church SJ, Lee SK, Ohl S, Patel S, Morgan TM, Alva A, Wakefield TW, Reichert Z, Holinstat M, Palapattu GS. Antisense oligonucleotides and nucleic acids generate hypersensitive platelets. Thromb Res. 2021 04; 200:64-71.
-
Nunnari G, Schnell MJ. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. Front Biosci (Schol Ed). 2011 06 01; 3(3):1032-7.
-
Ponnappa BC, Israel Y, Aini M, Zhou F, Russ R, Cao QN, Hu Y, Rubin R. Inhibition of tumor necrosis factor alpha secretion and prevention of liver injury in ethanol-fed rats by antisense oligonucleotides. Biochem Pharmacol. 2005 Feb 15; 69(4):569-77.
-
Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF, Rowland KM, Nair S, Tschetter LK, Fitch TR. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol. 2004 Dec 15; 22(24):4944-50.
-
Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton PJ, Watanabe T, Geary RS, Holmlund J, Dorr FA. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan; 9(1):115-23.
-
Fernandez V, Videla LA, Tapia G, Israel Y. Increases in tumor necrosis factor-alpha in response to thyroid hormone-induced liver oxidative stress in the rat. Free Radic Res. 2002 Jul; 36(7):719-25.
-
Ponnappa BC, Dey I, Tu GC, Zhou F, Aini M, Cao QN, Israel Y. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. J Pharmacol Exp Ther. 2001 Jun; 297(3):1129-36.